NEW Own TEM? Track every TEM payout — and your other stocks
Track your stocks, dividends, monitor DRIP shares, and project your passive income.
Start Free »

TEM | NASDAQ

$59.31 $0.00 | 0.00%

Next Earnings: Sep 14, 2026

Company Overview:

Market Cap: $0
Trailing PE: 0x
FWD PE:
Payout Ratio (TTM):
52-Week Range: $40.77 - $104.32

2.3 Year TEM Performance Metrics:

Total Return (with DRIP): 47.4% (18.36% CAGR)
Total Return (no DRIP): 47.4% (18.36% CAGR)
Share Price: 47.4% (18.36% CAGR)
Yield on Cost (with DRIP):
Total Invested: $10,000
Total Value (with DRIP): $14,735
Total Return $ (with DRIP): $4,735
TEM Total Return
1Y 2Y 5Y 10Y All
TEM Price Chart
1Y 2Y 5Y 10Y All
DRIPCalc.com
TEM Price

Unlock All Reports & Research Dividend Stocks.

Save 25% with annual plan (3 Months Free)
Pro
$171/yr ($14.25/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Stock Fundamentals
  • DCF valuation modeling
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
Start Free Trial
You save $57/yr (25%)
Most Popular
Premium
$288/yr ($24/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • Stocks Dashboard
Start Free Trial
You save $96/yr (25%)
Ultra
$576/yr ($48/mo)
7-day free trial
  • Everything in Premium
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Start Free Trial
You save $192/yr (25%)

TEM Earnings, Revenue, Cash & Debt, Shares Outstanding:

TEM - Revenue
TEM Revenue CAGR:1Y: 21.56%2Y: 51.81%5Y: 0.00%10Y: 0.00%
TEM - Earnings Per Share (EPS)
TEM EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
TEM - Net Income
🔒 Unlock
TEM Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
TEM - EBITDA
🔒 Unlock
TEM EBITDA CAGR:1Y: 396.52%2Y: 0.00%5Y: 0.00%10Y: 0.00%
TEM - Free Cash Flow
🔒 Unlock
TEM Free Cash Flow CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
TEM - Free Cash Flow / Share
🔒 Unlock
TEM Free Cash Flow / Share CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
TEM - Operating Income
🔒 Unlock
TEM Operating Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
TEM - Gross Profit
🔒 Unlock
TEM Gross Profit CAGR:1Y: 26.38%2Y: 84.53%5Y: 0.00%10Y: 0.00%
TEM - Shares Outstanding
🔒 Unlock
TEM Shares Outstanding CAGR:1Y: 5.20%2Y: 8.77%5Y: 0.00%10Y: 0.00%
TEM - Share Buybacks
🔒 Unlock
TEM Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
TEM - Stock-Based Comp
🔒 Unlock
TEM Stock-Based Comp CAGR:1Y: 141.02%2Y: -66.71%5Y: 0.00%10Y: 0.00%
TEM - Expenses
🔒 Unlock
TEM Expenses CAGR:1Y: 16.62%2Y: 17.69%5Y: 0.00%10Y: 0.00%
TEM - Revenue vs Net Income
🔒 Unlock
TEM - EPS vs FCF / Share
🔒 Unlock
TEM - EPS vs PE Ratio
🔒 Unlock
TEM - FCF vs FCF / Share
🔒 Unlock
TEM - FCF vs Stock Based Comp
🔒 Unlock
TEM - Cash & Debt
🔒 Unlock
TEM - Revenue by Segment
🔒 Unlock
TEM Revenue CAGR:1Y: 21.56%2Y: 51.81%5Y: 0.00%10Y: 0.00%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

TEM - REVENUE: Actual + Estimates
🔒 Unlock
TEM Actual Revenue CAGR:1Y: 21.56%2Y: 51.81%5Y: 0.00%10Y: 0.00%
TEM - EPS: Actual + Estimates
🔒 Unlock
TEM Actual EPS CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
TEM - NET INCOME: Actual + Estimates
🔒 Unlock
TEM Actual Net Income CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
TEM - EBITDA: Actual + Estimates
🔒 Unlock
TEM Actual EBITDA CAGR:1Y: 396.52%2Y: 0.00%5Y: 0.00%10Y: 0.00%

Ratios, Profit Margins & Return on Capital:

TEM - Net Profit Margin
🔒 Unlock
TEM Net Profit Margin CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%
TEM - Gross Profit Margin
🔒 Unlock
TEM Gross Profit Margin CAGR:1Y: 3.97%2Y: 21.55%5Y: 0.00%10Y: 0.00%
TEM - Price to Earnings
🔒 Unlock
TEM - Price To Sales Ratio
🔒 Unlock
TEM - Return on Capital Employed
🔒 Unlock
TEM - Return on Invested Capital
🔒 Unlock

Compare stocks side-by-side
 

Projected Future Returns & Dividends for TEM

Based on past 2.3-year performance, here are TEM growth metrics:

Share price CAGR of +18.36%
Dividend CAGR of +0%

Using TEM CAGR metrics, we can estimate that your initial $10000 investment, over the next 7 years, is modelled to grow as follows:

Projected over 7 years — based on 2.3 years of history.

TEM (DRIP)TEM - No DRIP
Current Price$59.31$59.31
Start Shares168.61168.61
Start Value$10,000$10,000
  
After 7 years:
Final Share Count168.61168.61
Dividends Payment$0.00$0.00
Annual Dividends$0$0
Yield on cost0.00%0.00%
Share Price$59.31$59.31
Total Dividends$0$0
Final Value$10,000$10,000

Estimated Future Value + Dividends - TEM

NOTE: Above numbers are our estimate based on TEM's Dividend and Price CAGR over past 2.3 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)
Pro
$171/yr ($14.25/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Stock Fundamentals
  • DCF valuation modeling
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
Start Free Trial
You save $57/yr (25%)
Most Popular
Premium
$288/yr ($24/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • Stocks Dashboard
Start Free Trial
You save $96/yr (25%)
Ultra
$576/yr ($48/mo)
7-day free trial
  • Everything in Premium
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Start Free Trial
You save $192/yr (25%)

Company Info

Tempus AI, Inc. (TEM) had its IPO on 2024-06-14, and is trader on NASDAQ stock exchange.

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

TEM website: https://www.tempus.com


Get Full Access to All Reports with DRIPCalc PRO

Save 25% with annual plan (3 Months Free)
Pro
$171/yr ($14.25/mo)
7-day free trial
  • Unlimited Portfolio Tracker
  • Portfolio - Lots/Sales/Dividends
  • Portfolio Auto-DRIP
  • Stock Fundamentals
  • DCF valuation modeling
  • Compare Stocks Side-by-Side
  • Revenue & EPS Estimates
Start Free Trial
You save $57/yr (25%)
Most Popular
Premium
$288/yr ($24/mo)
7-day free trial
  • Everything in Pro
  • YieldMax PNL Tracker
  • YieldMax NAV Erosion Alerts
  • Stocks Dashboard
Start Free Trial
You save $96/yr (25%)
Ultra
$576/yr ($48/mo)
7-day free trial
  • Everything in Premium
  • Group & weekly ETF estimates
  • YouTuber Mode
  • Trades summary + CSV export
  • Priority data & support
Start Free Trial
You save $192/yr (25%)